Highest-materiality recent filing
Ardelyx Q1 revenue $93.4M (+38% YoY); IBSRELA revenue $70.1M (+58% YoY)
Net loss $37.6M ($0.15/sh) vs $41.1M ($0.17/sh) Q1 2025; share-based comp $14.2M.
Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher
IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).
Ardelyx reports preliminary Q4 2025 IBSRELA sales ~$87M, XPHOZAH ~$28M; cash $265M
Preliminary unaudited U.S. net product sales: IBSRELA ~$87M Q4, ~$274M FY 2025.
Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised
Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).
Ardelyx appoints Sue Hohenleitner as CFO
Appointed Sue Hohenleitner as CFO effective Nov 4, 2025; she joins Oct 13, 2025.
Ardelyx Q2 revenue $97.7M (+33%), raises IBSRELA guidance; CFO to depart
Q2 total revenue $97.7M (+33% YoY); IBSRELA net sales $65M (+84% YoY); XPHOZAH net sales $25M (-33% YoY).
Ardelyx draws $50M term loan, secures $100M additional capacity from SLR
Immediate draw of $50.0M (Term E Loan) under Fifth Amendment to 2022 Loan Agreement.
Ardelyx shareholders approve equity plan amendment increasing share reserve by 10M shares
Shareholders approved first amendment to 2014 equity plan, raising authorized shares from 58.5M to 68.5M.
Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M
Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.
Ardelyx reports FY2024 revenue $333.6M; narrows net loss to $39.1M; provides 2025 guidance
Total revenue $333.6M in 2024, up from $124.5M in 2023; driven by IBSRELA ($158.3M) and XPHOZAH ($160.9M) sales.
Ardelyx Q3 revenue $98.2M; IBSRELA $40.6M, XPHOZAH $51.5M; net loss $0.8M
IBSRELA Q3 net sales $40.6M (+15% QoQ); full-year guidance set at $145-150M.
Ardelyx Q2 total revenue $73.2M, driven by IBSRELA $35.4M and XPHOZAH $37.1M
IBSRELA Q2 net sales $35.4M, up ~25% QoQ; XPHOZAH Q2 net sales $37.1M, up from $15.2M in Q1 2024.
Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment
Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.
Ardelyx Q1 product revenue $45.6M (IBSRELA $28.4M, XPHOZAH $15.2M); net loss $26.5M
Q1 product-related revenue $45.6M: IBSRELA $28.4M (+149% YoY), XPHOZAH $15.2M (first full quarter after Oct 2023 approval).
On April 28, 2025, the Company appointed Merdad Parsey, M.D., Ph.D, as a member of the Board of Directors (the “Board”) of Ardelyx, Inc., a Delaware corporation (the “Company”), effective immediately
The Company has appointed Joseph Reilly to replace Robert Felsch in his capacity as the Company’s Principal Accounting Officer effective November 15, 2024.
Mr. Felsch will remain with the Company and will transition to a senior financial advisor role within the Company
Max materiality 0.85 · Median 0.68 · Most common event earnings